-+ 0.00%
-+ 0.00%
-+ 0.00%
AIM ImmunoTech Says Phase 2 DURIPANC Topline Results Expected In Q1 2027, With Additional Clinical And Immune-Response Analyses Anticipated In Q3 2027
Share
Listen to the news

-SEC Filing

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending